VEGFA and wet macular degeneration: ,126,132,133 Similarly, some patients who received high-dose IVI of AAV2 driving expression of a soluble VEGF neutralizing protein (AAV2-sFLT01) (2 × 1010 vg) for wet AMD (ClinicalTrials.gov: NCT01024998) developed pyrexia and intraocular inflammation.